208 related articles for article (PubMed ID: 28650566)
41. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
42. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
[TBL] [Abstract][Full Text] [Related]
43. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
[TBL] [Abstract][Full Text] [Related]
44. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy.
Caruso S; Cianci S; Vitale SG; Fava V; Cutello S; Cianci A
Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):24-31. PubMed ID: 29436865
[TBL] [Abstract][Full Text] [Related]
45. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study.
Heikinheimo O; Inki P; Schmelter T; Gemzell-Danielsson K
Hum Reprod; 2014 Jun; 29(6):1182-8. PubMed ID: 24682613
[TBL] [Abstract][Full Text] [Related]
46. Immediate postpartum levonorgestrel intrauterine device insertion and breast-feeding outcomes: a noninferiority randomized controlled trial.
Turok DK; Leeman L; Sanders JN; Thaxton L; Eggebroten JL; Yonke N; Bullock H; Singh R; Gawron LM; Espey E
Am J Obstet Gynecol; 2017 Dec; 217(6):665.e1-665.e8. PubMed ID: 28842126
[TBL] [Abstract][Full Text] [Related]
47. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
[TBL] [Abstract][Full Text] [Related]
48. Use of 52-mg Levonorgestrel-Releasing Intrauterine System in Adolescents and Young Adult Women: 3-Year Follow-Up.
Oliveira ECF; Baêta T; Cotta RCF; Rocha ALL
J Pediatr Adolesc Gynecol; 2023 Feb; 36(1):45-50. PubMed ID: 36089114
[TBL] [Abstract][Full Text] [Related]
49. The levonorgestrel intrauterine system in nulliparous women.
Prager S; Darney PD
Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
[TBL] [Abstract][Full Text] [Related]
50. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
[TBL] [Abstract][Full Text] [Related]
51. Satisfaction and continuation with LNG-IUS 12: findings from the real-world kyleena
Stovall DW; Aqua K; Römer T; Donders G; Sørdal T; Hauck B; Llata ES; Kallner HK; Salomon J; Zvolanek M; Frenz AK; Böhnke T; Bauerfeind A
Eur J Contracept Reprod Health Care; 2021 Dec; 26(6):462-472. PubMed ID: 34528857
[TBL] [Abstract][Full Text] [Related]
52. Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?
Patseadou M; Michala L
Arch Gynecol Obstet; 2017 Mar; 295(3):529-541. PubMed ID: 27928678
[TBL] [Abstract][Full Text] [Related]
53. The 13.5-mg, 19.5-mg, and 52-mg Levonorgestrel-Releasing Intrauterine Systems and Risk of Ectopic Pregnancy.
Elgemark K; Graner S; McTaggart J; Ramirez Löfström J; Sörensen D; Envall N; Kopp Kallner H
Obstet Gynecol; 2022 Aug; 140(2):227-233. PubMed ID: 35852273
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
[TBL] [Abstract][Full Text] [Related]
55. [Efficacy and safety of low-dose levonorgestrel-releasing intrauterine system in Chinese women: a multicenter, single-arm, open labeled interventional trial].
Qian CF; Fan GS; Liao QP; Wu SY; La DD; Di W; Dong BH; Liu HW; Tang LD; Xiong ZA; Zhang HW; Hu YL; Yang NM; Ren ML; Shi H; Deng GP; Huang ZR
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):409-413. PubMed ID: 29961284
[No Abstract] [Full Text] [Related]
56. Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use.
Mejia M; McNicholas C; Madden T; Peipert JF
Contraception; 2016 Nov; 94(5):556-560. PubMed ID: 27364099
[TBL] [Abstract][Full Text] [Related]
57. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial.
Gupta JK; Daniels JP; Middleton LJ; Pattison HM; Prileszky G; Roberts TE; Sanghera S; Barton P; Gray R; Kai J;
Health Technol Assess; 2015 Oct; 19(88):i-xxv, 1-118. PubMed ID: 26507206
[TBL] [Abstract][Full Text] [Related]
58. A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
Fan G; Kang S; Ren M; Weisberg E; Lukkari-Lax E; Roth K; Shin S
Contraception; 2017 Apr; 95(4):371-377. PubMed ID: 27913229
[TBL] [Abstract][Full Text] [Related]
59. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial.
Heliövaara-Peippo S; Halmesmäki K; Hurskainen R; Teperi J; Grenman S; Kivelä A; Tomas E; Tuppurainen M; Paavonen J
BJOG; 2010 Apr; 117(5):602-9. PubMed ID: 20156209
[TBL] [Abstract][Full Text] [Related]
60. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
